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Chlamydia trachomatis is an obligate intracellular bacterial pathogen that infects both
humans and domestically important animals. Research in the field has, until more
recently, been hindered by a lack of genetic tools. We have modified Sigma’s
TargeTron™ Gene Knockout System, which utilizes a mobile group II intron for sitespecific insertion and gene inactivation, for use in C. trachomatis. As proof of principle,
we used the system to inactivate incA, creating mutant strains DFCT3 and DFCT4
(independent clones both carrying incA::GII[bla]). IncA is a chlamydial inclusion
membrane protein involved in homotypic fusion of inclusions when cells are infected
with more than one bacterium. Genotypic and phenotypic analyses were performed to
ensure successful intron insertion into incA and loss of IncA function. Further
characterization of the incA::GII(bla) mutant examined its pathogenicity relative to the
wild type strain and indicated that the mutant was attenuated for growth in a mouse
infection model, but not in a cell culture infection model. Complementation of the incA
mutant confirmed that the phenotype differences between the wild type strain and the
mutant were due to inactivation of incA. As incA mutants arise spontaneously during
human infections, future work will focus on the role of IncA in pathogenesis using the
mutant strains derived from this study.
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CHAPTER 1
INTRODUCTION

Public health significance
Chlamydia spp. are obligate, intracellular Gram negative bacterial pathogens that
are responsible for a variety of human diseases and diseases that affect economically
important domestic animals (Table 1.1) (Longbottom and Livingstone, 2006). Of
particular importance to human health is Chlamydia trachomatis (causative agent of
trachoma and sexually transmitted infections [STIs]), the leading cause of reportable
bacterial infections worldwide. It is also responsible for the most common reportable
bacterial sexually transmitted infection in the United States (Brunham and Rappuoli,
2013). C. trachomatis may cause dangerous long-term complications if left untreated. In
women, it increases the risk of pelvic inflammatory disease, infertility, and ectopic
pregnancy (Chow et al., 1990; Healy et al., 1994; Paavonen and Lehtinen, 1996). In
men, it can cause urethritis and lead to epididymitis and prostatitis, as well as
decreased sperm viability (Mackern-Oberti et al., 2013). In addition to directly causing
disease, co-infection with C. trachomatis and human papillomavirus (HPV) puts the
affected female at an increased risk for cervical cancer (Samoff et al., 2005). Untreated
C. trachomatis infection also elevates efficiency of HIV transmission (Schust et al.,
2012). These dangers are compounded by the frequently asymptomatic presentation of
chlamydial sexually transmitted infections (Bébéar and de Barbeyrac, 2009).
Chlamydia trachomatis is composed of several serological variants, known as
serovars. Serovars A-C cause ocular infections, which are responsible for the most
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common cause of preventable blindness worldwide (Burton and Mabey, 2009).
Serovars D-K are sexually transmitted variants of C. trachomatis. Serovars L1-L3 cause
the systemic sexually transmitted infection known as lymphogranuloma venereum
(LGV) (Bébéar and de Barbeyrac, 2009).

Table 1.1: Chlamydia species and diseases
Organism
C. trachomatis

Host
Humans

C. pneumoniae
C. muridarum
C. psittaci
C. abortus1
C. suis2
C. pecorum

Humans
Hamsters, mice
Birds, humans
Ruminants, humans
Swine
Ruminants,
marsupials
Domestic cats
Guinea pigs

C. felis1
C. caviae
1
2

Disease
Trachoma, urethritis, pelvic inflammatory
disease, ectopic pregnancy, lymphogranuloma
venereum
Pneumonia, bronchitis
Pneumonia
Psittacosis, pneumonia
Fetal death, abortions
Conjunctivitis, pneumonia, enteritis
Abortion, conjunctivitis, pneumonia, infertility
Conjunctivitis, rhinitis
Ocular inflammation

Vaccine commercially available
Some strains carry the tetR gene, tet(C)

Bacterial growth and development
The Chlamydia undergo a unique biphasic developmental cycle in which the
infectious, nonreplicative elementary body (EB) comes into contact with and attaches to
a host cell (Figure 1.1A) (Abdelrahman and Belland, 2005). Upon contact, the EB is
endocytosed where upon it resides within a host membrane-derived vesicle termed an
inclusion (Figure 1.1B-C). For Chlamydia trachomatis, it is during the first few hours
2

within the inclusion that the EB will differentiate into the non-infectious, replicative
reticulate body (RB) (Figure 1.1D). The RBs undergo rounds of replication via binary
fission and the inclusion size increases to accommodate the growing number of
bacteria. At about 18 hours post infection, the RBs begin asynchronously differentiating
back into EBs (Figure 1.1E-H). Finally, at about 40 to 48 hours after infection is initiated,
lysis of the inclusion and host cell allows the EBs to escape and for the infectious cycle
to begin again in a new cell (Figure 1.1I). Length of the developmental cycle varies from
about 40 to 72 hours depending upon the species.
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Figure 1.1: Chlamydia developmental cycle. Modified and used with permission of
Derek Fisher (Southern Illinois University).

Chlamydia spp. possess a type-three secretion system (T3SS) (Mueller et al.,
2014). The T3SS plays an important role in modifying the inclusion at the interface of
the host cytosol and inclusion membrane, a significant point for interaction between the
cell and the bacterium. A group of proteins termed inclusion membranes proteins, or
Incs, are secreted by the T3SS early in infection and localize to the inclusion membrane
(Mital et al., 2013). There are over 50 Incs predicted within the C. trachomatis genome.
The Incs all have a characteristic bi-lobed hydrophobic domain of 40 amino acids or
4

more despite having a surprising lack of sequence similarity (Figure 1.2) (Ronzone and
Paumet, 2013). Currently, the function of only a small portion of the Incs is known
(Table 1.2) (Agaisse and Derré, 2014; Hackstadt et al., 1999; Lutter et al., 2013; Mital et
al., 2013; Rzomp et al., 2006; Scidmore and Hackstadt, 2001).

Figure 1.2: General Inc protein characteristics. The bi-lobed hydrophobic
transmembrane (TM) region associates with the inclusion membrane while the Cterminal region, whose function is Inc-specific, is exposed to the host cytosol and allows
for interaction with host components. The IncA’s SNARE-like domains enable IncA to
promote homotypic fusion of multiple inclusions, as well as block host endocytic
SNARE-mediated membrane fusion (Ronzone and Paumet, 2013).
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Table 1.2: Known functions of C. trachomatis Inc proteins
Known biological function
C. trachomatis Inc proteins
IncA
Homotypic fusion
IncD
CERT recruitment
IncG
Adapter protein 14-3-3β recruitment
CT228
MYPT1 recruitment
CT229
Rab4 recruitment

Typically, when more than one EB infects a single host cell, the multiple
inclusions will fuse until only a single inclusion is visible within the cell. IncA, a T3SS
substrate, has been implicated in the process of homotypic fusion. Experiments
reported by Hackstadt et al. used microinjections with rabbit polyclonal antibodies
against three different Inc proteins into C. trachomatis-infected HeLa cells (Hackstadt et
al., 1999). The infected cells microinjected with the anti-IncA antibodies displayed
multiple, non-fusing inclusions. In addition, clinical isolates have been found that lack a
functional IncA protein (Suchland et al., 2000). Sequencing of these isolates revealed a
variety of modifications to the incA gene ranging from frameshift mutations to base
changes resulting in early termination during translation or deletions of up to 671 base
pairs (bp) leading to the production of a truncated IncA (Rockey et al., 2002). Mutants
also have been identified with nucleotide changes resulting in a single amino acid
difference within the characteristic hydrophobic domain that significantly modifies its
hydrophobicity (Suchland et al., 2000). These isolates produce multiple, non-fusogenic
inclusions in cells infected with more than one EB.
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Genetic tools
Despite the public health relevance of Chlamydia spp., research on these
pathogens has been greatly hindered by two factors: 1) their obligate, intracellular
lifestyle, which has made all previous attempts at developing a system of long-term
axenic growth unsuccessful and 2) a paucity of genetic tools. However, researchers in
the field have recently made great strides in addressing the need for useful genetic tools
and limited growth under axenic conditions has now been achieved (Agaisse and Derré,
2013; Kari et al., 2011; Mishra et al., 2012; Omsland et al., 2012; Wickstrum et al.,
2013).
Within the past two years, Chlamydia cryptic plasmid-based expression platforms
have been developed to allow for the expression of foreign and recombinant genes
(Agaisse and Derré, 2013; Wickstrum et al., 2013). In addition, chemical mutagenesis
using ethyl methanesulfonate (EMS) has been successfully employed for forward and
reverse genetic approaches, and antisense RNA has been used for gene silencing (Kari
et al., 2011; Mishra et al., 2012). However, the field still lacked a method of targeted
chromosomal gene mutation.
A mobile group II intron from Lactococcus lactis was previously modified for use
in targeted gene disruption in prokaryotes (Lambowitz and Zimmerly, 2004). Bacterial
genomes may contain both group I and group II introns. These are mobile catalytic RNA
elements (Hausner et al., 2014; Lambowitz and Zimmerly, 2004). The ability of mobile
group II introns to splice from an RNA sequence depends on the assistance of an
intron-encoded protein (IEP) that is located within the intron sequence (Lambowitz and
Zimmerly, 2004). Once excised, the intron RNA is able to splice directly into the target
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location within a DNA sequence. Recognition of the DNA by the intron is based on
sequence similarity between the DNA and specific sites within the intron, known as the
intron and exon-binding sites (IBS and EBS) (Figure 1.3A) (Lambowitz and Zimmerly,
2004). It is then reverse transcribed by the IEP, which in L. lactis is performed by the
LtrA. Mobile group II introns share a conserved secondary structure essential for their
catalytic activity despite minimal sequence similarity (Lambowitz and Zimmerly, 2004).
Unlike group II introns, group I introns are self-splicing, eliminating the need for protein
assistance to move from one location within the genome to another (Hausner et al.,
2014). Like group II introns, group I introns lack sequence similarity while retaining
similar secondary structure. The insertion of group I or group II introns within an open
reading frame may result in a truncated or total lack of protein if the intron does not
splice out of the RNA (Saldanha et al., 1993). However, since both may be spliced out,
protein production and function is typically restored under wild type conditions (Hausner
et al., 2014; Lambowitz and Zimmerly, 2004).
To utilize the specificity and efficiency of group II introns as a mutagenesis tool,
modifications were made. Unlike the wild type L. lactis intron, the ltrA ORF is removed
from within the intron and placed at the 3’ end of the exon (Figure 1.3B) (Perutka et al.,
2004). This ensures that, upon successful intron insertion and plasmid loss, the LtrA is
lost and thus unable to splice the intron from the chromosome. In place of the ltrA ORF,
an antibiotic resistance gene is inserted to allow for mutant selection. The plasmid has
an origin of replication that, ideally, allows for propagation within E. coli, but not within
the organism in which the target gene resides, ensuring loss of the plasmid upon intron
mobilization and insertion. The plasmid also contains an antibiotic resistance cassette
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located outside of the group II intron to allow for selection when propagating within E.
coli (Perutka et al., 2004). This system is marketed as TargeTron™ by Sigma and relies
upon a proprietary algorithm that allows for retargeting of the intron, via PCR and
restriction digestion, based on the sequence of the gene to be inactivated.

Figure 1.3: Wild type and modified Lactococcus lactis group II intron. (a) A simplified
wild type L. lactis group II intron illustrates the location of the DNA recognition sites
(IBS, EBS2, EBS1δ), as well as the location of the IEP (LtrA) within the intron. (b) A
plasmid containing the modified group II intron in which the IEP has been moved and
restriction sites added. Introns are retargeted by changing the sequence between the
HindIII and BsrGI sites and “gene cargos” can be inserted at the MluI site.

This project began with an attempt to further modify this system for use in
Chlamydia and as proof of principle we used the system for the site-specific inactivation
of incA in C. trachomatis L2 434/Bu. The resulting incA::GII(bla) mutant displayed a
9

non-fusogenic phenotype when one cell was infected with multiple EBs. Using a variety
of methods, the stability of the insertion was subsequently demonstrated (at both the
genotype and phenotype levels) over repeated passages in cell culture and in an animal
infection model in the absence of selection. More recent studies have begun to assess
the pathogenicity of the mutant compared to that of the wild type parental strain using
both cell culture and a mouse vaginal tract infection model. In addition, we have
complemented the mutant to ensure that the growth phenotypes observed were due to
the incA::GII(bla) mutation and not a second site mutation or polar effects.

Aims
The goals of this project were to develop a method for targeted gene inactivation
in Chlamydia and to demonstrate the utility of this approach for studying the biology of
this important pathogen.
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CHAPTER 2
MATERIALS AND METHODS

Culturing conditions
Mouse fibroblast L2 cells were routinely grown at 37oC with 5% CO2 in
Dulbecco’s Modified Eagle Medium (DMEM) (HyClone, Thermo Scientific™) with
GlutaMAX™ (Gibco ®, Life Technologies ™) supplemented with 10% fetal bovine
serum (HyClone, Thermo Scientific™). PCR with degenerate primers to the
Mycoplasma spp. 16s rRNA was used periodically to check the cells for mycoplasma
contamination. All primers except for those listed in text are listed in Johnson and Fisher
(Johnson and Fisher, 2013).
C. trachomatis was grown in L2 cells. Stocks were titered via the inclusion
forming unit (IFU) assay and stored at -80oC in sucrose phosphate glycerine buffer
(SPG, 0.19 mM KH2PO4, 0.36 mM K2HPO4, 0.245 mM L-glutamic acid, 10.9 mM
sucrose).
E. coli strains were grown at 37oC on Luria-Bertani (LB) agar plates or in LB
broth with antibiotics, as appropriate (chloramphenicol at 20 µg/mL, kanamycin at 50
µg/mL, spectinomycin at 100 µg/mL, and/or ampicillin at 100 µg/mL [all from Fisher
BioReagents]).

IFU assay
Chlamydia samples were diluted in infection medium (DMEM, 10% FBS, 1×
nonessential amino acids, and 0.2 µg/mL cycloheximide). 200 µl of the samples were
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added per well of a black 96-well plate containing a confluent mouse L2 monolayer. To
encourage simultaneous infection of cells, the plate was centrifuged at 545 × g for one
hour and then incubated at 37oC for 24 hours (T0 = start of centrifugation). After the 24
hour incubation, the infection medium was aspirated from the 96-well plate via suction
and replaced with 200 µl of ice-cold methanol. The plate was incubated at room
temperature for one hour or overnight at 4oC.
The methanol was removed via suction and one drop of PathfinderTM Chlamydia
Culture System (Bio-Rad) was added to each infected well and incubated at room
temperature in the dark for 30 minutes. The antibody was dumped from the plate and
wells were rinsed with deionized water. The plate was blotted to remove excess liquid
and one drop of mounting medium was added to each well (glycerol,10% phosphate
buffered saline). Plates were either examined immediately or stored in the dark at 4oC
and examined within 24 hours.
Plates were examined under a fluorescent microscope at 400× magnification
under green fluorescence. Inclusions were counted in ten random fields per well and the
titer determined via the following formula:
(total IFU counted) × 233.96 fields per well × dilution factor correction = IFU/mL
(total fields counted)

TargeTron™ plasmid construction
The base TargeTron™ vector pACD4K-C (Sigma) was modified for use in
Chlamydia by first removing the kanamycin resistance RAM cassette. The vector was
digested with MluI (molecular biology reagents obtained from Thermo Scientific™
Fermentas unless noted otherwise), run on an agarose gel (using the GeneJET Gel
12

Extraction and Purification Kit, Thermo Scientific™), and purified. The digested, linear
plasmid lacking the cassette was then recircularized via ligation with T4 DNA ligase.
The ligation was transformed into E. coli DH5α and selected on LB plates containing
chloramphenicol. Colonies were then patched onto both LB agar plates containing
chloramphenicol and LB agar plates containing kanamycin. A clone found to be
sensitive to kanamycin, but resistant to chloramphenicol was chosen and grown for
plasmid isolation (using GeneJET Plasmid Miniprep Kit, Thermo Scientific™). RAM
cassette loss was confirmed via PCR using primers GIIFtest and GIIRtest. This plasmid
was designated pDFTT1.
pDFTT1 was further modified with the addition of a chlamydial promoter
upstream of the GII 5’ exon. Genomic DNA from plaque-purified, clonal C. trachomatis
434/Bu L2 strain ACE051 (from Anthony Maurelli, Uniformed Services University of the
Health Sciences) was used to clone the 264 bp region upstream of the CTL0655 start
codon. Primers CTL0655 proF and proR were used in the PCR reaction with Platinum
Taq DNA Polymerase, High Fidelity. HindIII and XbaI were used to digest both the PCR
product as well as pDFTT1. After agarose gel purification, the digested PCR fragment
was ligated into the digested pDFTT1. The ligation product was then transformed into E.
coli DH5α and plated onto LB agar plates containing chloramphenicol to select for
transformants. PCR was used to screen for the presence of the insert and a positive
clone was grown for plasmid preparation before further confirmation via sequencing.
This plasmid was designated pDFTT2.
The bla cassette was then moved into pDFTT2 to confer ampicillin resistance to
Chlamydia upon successful intron insertion. pGFP::SW2 (gift of Ian Clarke, University of
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Southampton) was used as template in a PCR reaction with primers blaF and blaR and
Phusion High-Fidelity PCR Master Mix to generate a fragment containing the bla gene.
Both PCR fragment and pDFTT2 were digested with MluI, run on an agarose gel and
purified. The bla-containing fragment was then moved into pDFTT2 via ligation.
Transformants were selected on LB agar plates containing both ampicillin and
chloramphenicol and screened via PCR using primers blaF and GIIRtest. pDFTT2(bla)
was then sequenced for verification.

Intron retargeting to incA
The C. trachomatis incA DNA sequence was submitted to the TargeTron™
Design Site and its proprietary algorithm used to determine the optimal site for intron
insertion. Of the generated results, the insertion site was chosen based on the closest
proximity to the 5’ start codon, as well as the lowest E-value (0.191).
Three primers were generated based on the insertion site chosen (1608|1609IBS, 1608|1609-EBS 1d, 1608|1609-EBS2) and used along with primer EBS universal
to generate a 350 bp PCR product. The product, as well as pDFTT2(bla), was digested
with HindIII and BsrgGI. They were then run on an agarose gel, purified, and ligated to
generate the retargeted pDFTT3. The ligation product was transformed into E. coli
DH5α and clones isolated. Primer T7 pro was then used to sequence verify the clones.

TargeTron™ transformation and selection
1×107 EBs were pipetted into a 1.5 mL microcentrifuge tube along with 3 µg
pDFTT3 plasmid DNA. Molecular grade, sterile water was added to a volume of 160 µL
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followed by 40 µL 5× CaCl2. The solution was mixed by pipetting up and down 10 times
and then left for 30 minutes at room temperature. After the 30 minute incubation, 33.3
µL of the transformation was added to 2 mL of ice-cold SPG for each well to be infected.
This was then used to infect a confluent fibroblast L2 cell monolayer in a 6-well tissue
culture plate via centrifugation for 1 hour at 545 × g. This infection is passage zero (P0).
The mix was replaced with 2 mL DMEM/FBS and the plate incubated at 37oC with 5%
CO2.
At 12 hours post infection (T0 = start of centrifugation), medium was replaced with
2 mL DMEM/FBS supplemented with appropriate selection antibiotic (1 µg/mL ampicillin
or 200 µg/mL spectinomycin).
Between 40-44 hours post infection, P0 was harvested. Sterile glass beads were
added to the wells and the plate was rocked and swirled gently until no cells remained
attached. The medium was transferred to a 50 mL conical tube and lysed via sonication
with a 1/8-inch probe at 20% duty for 20 seconds. The sample was then centrifuged for
20 minutes at 4oC at 10,000 × g. The supernatant was removed and discarded and the
pellet suspended in 2.5 mL SPG by vortexing and pipetting.
The P0 harvest was then used to infect a confluent fibroblast L2 monolayer in a
T75 flask. The flask was infected via rocking for two hours at 37oC with 5% CO2 (P1).
The medium was then replaced with 20 mL of complete medium (DMEM, 10% FBS, 0.2
µg/mL cyclohexamide, 1× nonessential amino acids) with 1 µg/mL ampicillin. The flask
was incubated for 40-44 hours at 37oC with 5% CO2.
P1 was harvested by adding sterile glass beads to the flask and rocking until all
cells appeared detached. The medium was transferred to a 50 mL conical tube and
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lysed via sonication at 30% duty with a 1/8-inch probe for 20 seconds. The sample was
centrifuged and suspended as for P0 harvest and used to infect P2 as for P1.
P2 was harvested as described for P1 harvest and used to infect P3 as described
above, but with an increased concentration of ampicillin at 5 µg/mL. P3 was harvested
as above and 1/3 of the harvest used to infect P4 as an additional round of enrichment,
but with ampicillin again at 1 µg/mL.
P4 was harvested, titered via IFU assay, and used in plaque assays to obtain
plaque-purified clones. Plaque assay infections and overlay feeds were done either in
the presence or absence of 5 µg/mL ampicillin. Plaques were picked and expanded in
the absence or presence of drug to match the conditions in which each was plaque
purified. Expansion continued until each clone was used to infect eight T175 flasks
which were then harvested, titered via IFU assay, and stocked at -80oC in SPG.

Mutant genotype analysis
Genomic DNA was purified from clones DFCT3 and DFCT4 and ACE051 using
the DNeasy Blood & Tissue Kit (Qiagen) and quantified via A260 nm absorbance using
a Biotek Syngery HT microplate reader. PCR reactions were carried out using 2× PCR
Master Mix (Thermo ScientificTM) and primers at 0.5 µM. Genomic DNA was used at 50
ng and plasmid DNA was used at 10 ng per reaction. PCR products were run on an
agarose gel and imaged via UV transillumination following ethidium bromide staining.
To sequence the insertion sites in the incA::GII(bla) clone, the ACE051, DFCT3,
and DFCT4 incA regions were amplified. PCR with primers incAseqF and incAseqR
was used to generate fragments containing incA that was flanked by StuI restriction
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sites. The PCR products were run on an agarose gel and purified prior to StuI digestion.
StuI was also used to digest pUC18. The digested PCR product was then ligated into
the StuI-digested pUC18 and transformed into E. coli DH5α. Transformants were
selected on LB agar plates containing ampicillin, which were also used for blue-white
screening. Transformants were further verified by PCR and grown up for plasmid
isolation. The isolated recombinant plasmids pUC18incA, pUC18incA::GII(bla)DFCT3, and
pUC18incA::GII(bla)DFCT4 were sent for Sanger sequencing with primers GIIFtest,
GIIRtest, blaF2, pUCF, and pUCR.
For Southern blot analysis, one of three enzymes (PstI, SphI, or SacI) was used
to digest 2 µg of genomic DNA, which was then run on a 0.7% agarose gel. Ethidium
bromide was used to stain the gels which were then viewed with a Spectrolinker ™ UV
transilluminator (BioRad ChemiDoc MP System). DNA was then transferred from the gel
to positively charged nylon membranes. DNA was crosslinked to the membrane using a
UV crosslinker set to “optimal crosslink.” The membranes were probed for DNA
fragments containing incA or bla by overnight treatment with DIG-labeled DNA probes
at 42oC. High-stringency washes were carried out at 65oC before probe detection.
Rosche’s alkaline phosphatase anti-DIG antibody-based DIG Nucleic Acid Detection Kit
was used for detection of bound probes. Addition of the precipitating chromogenic
substrate nitroblue tetrazolium chloride was used to visualize bound antibody.
Deionized, distilled water was added to stop the reaction. Photographs of the blots were
taken using a BioRad ChemiDoc MP System.
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Western blotting of IncA and MOMP
Fibroblast L2 cells were grown in a 24-well culture plate until the monolayer
reached ~90% confluence. Trypsin was added to three of the wells to detach cells.
Trypan blue was added to the detached cells and used for counting. A multiplicity of
infection (MOI) of ten was then used to infect wells with ACE051, DFCT3, or DFCT4,
diluted in 1 ml complete infection medium, via centrifugation for one hour at 545 × g at
room temperature. Cells were incubated for 24 hours post infection at 37oC with 5%
CO2. A Leica DMIL inverted microscope was used to view cells. Photos were taken at
400× with a Leica EC3 camera fitted to the microscope and utilizing imaging software
Leica LASV4.1 for analysis.
For Western blotting, the medium was aspirated from the wells. The wells were
washed with PBS, 250 µL of 1× Laemmli buffer (containing 358 mM β-mercaptoethanol)
was added, and wells were scraped with a pipet tip to harvest the cells and bacteria.
Samples were transferred to Eppendorf tubes and heated for five minutes at 95oC after
sonication. Samples were run in triplicate on 12% SDS-PAGE gels to allow for
Coomassie Brilliant Blue staining and anti-MOMP and anti-IncA Western blotting. One
gel was stained with Coomassie Brilliant Blue and imaged to ensure equal loading of
the samples. The remaining gels were processed for Western blotting. The samples
were transferred from the SDS-PAGE gels to nitrocellulose membranes. The
membranes were blocked with 5% milk Tris-buffered saline (MTBS). Rabbit anti-IncA
(gift of Dr. Raphael Valdivia, Duke University) and mouse anti-MOMP antibodies (from
Abcam, gift of Wiley Jenkens, Southern Illinois University) were diluted at 1:200 and
1:1000, respectively, in MTBS and used to probe the gels overnight at 4oC. Membranes
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were washed with TBS/Tween-20 (0.05% V/V). Secondary goat anti-rabbit-IgG-HRPconjugated antibody (Thermo ScientificTM Pierce, IncA blots) or anti-mouse-IgG-HRPconjugated antibodies (Millipore, MOMP blots) were diluted in MTBS at 1:5000 and
used to probe the blots for one hour at room temperature. Blots were washed with
TBS/Tween-20, then TBS, and finally treated with a chemiluminescent substrate
(SuperSignal WestPico, Thermo ScientificTM Pierce). Processed blots were viewed and
imaged with a BioRad ChemiDoc MP. Three independent infections were performed to
assess IncA production.

Light and immunofluorescence microscopy of mutants
Fibroblast L2 monolayers in a 24-well tissue culture dishes, with some wells
containing acid-treated glass coverslips, were infected as for Western blotting. Cells
were infected at MOIs of 0.01 and five, for time points at 24 and 48 hours, and an MOI
of ten for the 24 hour time point only. Infected replicate wells without coverslips were
viewed and imaged under phase contrast microscopy at 400× magnification. For
immunofluorescence (IF) microscopy, cells were fixed and permeabilized as previously
described. Chlamydia were immunodetected by treatment first with a primary mouse
anti-MOMP antibody (Abcam), then by a Texas-Red-conjugated secondary donkey-antimouse IgG antibody (Thermo ScientificTM) and finally stained with DAPI. Coverslips
were then mounted onto glass slides using ProLong Gold anti-Fade (Life
TechnologiesTM) and viewed using a Leica DM4000 fluorescent microscope. Coverslips
were imaged with a QImaging QiClick Mono (QImaging) under oil immersion at 630×
magnification. Images were processed with QImaging software (QImaging).
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Complementation
A fragment which included wild type incA was cut from vector pUC19::incA via
restriction digestion using KpnI and SalI. This fragment also contained a 47 bp
upstream region in an attempt to include the incA promoter, the exact location of which
is unknown. p2TK2-SW2 (gift of Isabelle Derré, Yale School of Medicine) was similarly
digested with KpnI and SalI and both digested vector and incA fragment were run on a
0.7% agarose gel and purified. The incA fragment was then ligated into digested
p2TK2-SW2. The ligation product was then transformed into E. coli DH5α which was
grown for plasmid isolation. p2TK2-SW2::incA was sent for Sanger sequencing using
primers p2tkseqF and p2tkseqR (5’-GTTCTTTCCTGCGTTATCCC-3’; 5’TTGAAGCGCTCCGGATAGTG-3’, respectively).
To introduce the complementation and empty p2TK2-SW2 control vectors into
DFCT9, the incA::GII(aadA) mutant strain, the same chemical transformation method
was used as for the TargeTron™ transformation and selection. The recombinant strain
phenotypes were examined via phase contrast microscopy under 400× magnification
and images taken. The subsequent recombinant strains are DFCT6 (incA::GII[aadA]
p2TK2-SW2) and DFCT7 (incA::GII[aadA] p2TK2-SW2::incA).

Plaque Assays
60 mm plaque dishes with confluent L2 monolayers were infected with C.
trachomatis via rocking for one hour at 37oC. 6 mL of overlay (0.5% SeaKem agarose,
1× DMEM, 10% FBS, 1× NEAA, 0.2 µg/mL cycloheximide, and antibiotics as
appropriate) was added after infection and allowed to solidify for 20 minutes at room
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temperature before incubation at 37oC with 5% CO2. Plaques were fed with an
additional 3 mL of overlay on days five and ten. On day 15, 1.5 mL neutral red was
added to each dish and incubated for three hours at 37oC with 5% CO2. Neutral red was
then aspirated, overlay removed and discarded, and dishes allowed to dry overnight.

Measuring plaque size
Processed, dried plaque dishes were overturned and viewed on top of a light
source. Plaques were measured at their longest point to the nearest tenth of a
millimeter with a Peak Optics 7× loupe. Ten random plaques were measured per dish.
Measurements were taken from duplicate plaque dishes within each trial over a series
of three trials and then averaged.

Plaque expansion
For plaque picking, 60mm plaque dishes were infected as described above, but
were not processed with the addition of neutral red after the overlay removal on day 15.
10 µL of SPG was added to a single plaque on the dish, gently scratched with a pipet
tip, and pipetted up and down several times before freezing at -80oC until further
expansion.
Each harvested plaque was used to infect an individual well in a confluent 24well plate via centrifugation for one hour at 545 × g before incubation at 37oC with 5%
CO2. At 40 hours post infection, infected wells were harvested via addition of 500 µl
Trition X-100 for five minutes and scraping with a pipet tip for ~20 seconds. Harvests
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were centrifuged for five minutes at 13,000 × g at 4oC. Pellets were washed once with 1
mL PBS and suspended in 500 µL SPG and stored at -80oC.

Progeny production assay
Serial dilutions of wild type C. trachomatis and DFCT3 prepared in SPG were
used to infect a 24-well plate with confluent L2 monolayers via centrifugation at 545 × g
for one hour. 100 µL of each dilution was stored at -80oC for future titer of actual IFU
input. Wells were visually observed and those with an MOI closest to 0.1 and three to
five were chosen for harvest at 40 hours post infection. Harvests were performed via
addition of 500 µl Triton X-100 for five minutes and scraping with a pipet tip for ~20
seconds. Harvests were centrifuged for five minutes at 13,000 × g at 4oC. Pellets were
washed once with 1 mL PBS and suspended in 500 µL SPG and stored at -80oC until
titering via IFU assay. Three separate infections were performed, each trial in duplicate.
Harvests were titered in triplicate.

Mouse infections
BALB/c mice were pretreated with Depo-Provera to synchronize estrus and
infected vaginally with 3×106 IFU of wild type C. trachomatis or DFCT3 (stocks prepared
and provided by D. Fisher and the author). Vaginal swabs were taken every three days
from day three through day 33 post infection. Swabs were used to infect McCoy cells for
titering via IFU assay. Two trials were performed and each trial had five or six mice per
experimental group. Infections and titering were performed by Dr. Laxmi Yeruva
(University of Arkansas for Medical Sciences).
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Mouse swab expansions
Swabs were used to infect wells in a 24-well plate with a confluent L2 monolayer.
Wells were harvested at 40 hours post infection via addition of 500 µL Triton X-100 for
five minutes and scraping with a pipet tip for ~20 seconds. Harvests were centrifuged
for five minutes at 13,000 × g at 4oC. Pellets were washed once with 1 mL PBS and
suspended in 1 mL SPG and stored at -80oC until further expansion.
Harvests were used to infect L2 cells in 24-well plates and harvested as before. If
inclusions could be detected visually, harvests were used to infect L2 cells in 6-well
plates. Once a sufficient number of inclusions were present, EBs were harvested by
addition of glass beads and hand rocking to dislodge cells. SPG was added to 1× and
harvests were stored at -80oC until further processing.
The inclusion phenotype was visually observed under phase contrast light
microscopy at 400× magnification once an MOI of >1 was reached. Photos were taken
with a Leica LASV4 camera. The genotypes were tested using PCR on DNA purified
from harvests via Qiagen DNeasy Blood & Tissue Kit.
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CHAPTER 3
RESULTS

Generating an incA::GII(bla) mutant
Mutants were obtained through chemical transformation, ampicillin selection, and
isolated via plaque assay. Two plaque-purified mutants, DFCT3 and DFCT4, were
chosen for additional analysis.

Mutant confirmation
It was important to examine the genotype and phenotype of the incA::GII(bla)
mutants after expansion and harvest. Intron stability in the clone expanded in the
absence of selection would dictate whether or not mutants would be stable in the
absence of selection during animal infection studies. Also, the desirability of this system
lies in its ability to target with great specificity, making it essential to confirm its actual
insertion location in the obtained clones.
Successful insertion of the intron was confirmed first through a series of PCR
reactions (Johnson and Fisher, 2013). Primers were used to amplify a portion of incG,
which is located near incA within the C. trachomatis genome, indicating that successful
insertion of GII(bla) within incA had no effect on surrounding regions (Figure 3.1,
Reaction 1). The cryptic plasmid was found to remain present in both the parental and
mutant strains despite introduction of the TargeTron™ plasmid, pDFTT3 (Figure 3.1,
Reaction 2). The size shift of incA due to intron insertion was apparent when using
primers that sit within incA, flanking the insertion site (Figure 3.1, Reaction 3). Reactions
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4 and 5 demonstrated the presence and orientation of the intron within incA in the two
mutant strains using two different primer sets in which one primer was located within the
intron and the other within the incA ORF (Figure 3.1). Primers specific for the intron
yielded products for only the mutant strains and pDFTT3, indicating a lack of intron
presence within the parental strain ACE051 (Figure 3.1, Reaction 6). Finally, primers
specific for pDFTT3 only yielded product when plasmid DNA was used in the PCR
reaction, indicating plasmid loss in the mutant strains after intron insertion (Figure 3.1,
Reaction 7).
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Figure 3.1: PCR verification of incA::GII(bla) mutants plaque-purified with or without
ampicillin selection. Isolated genomic DNA from both mutant and parental strains, along
with pDFTT3, were used in a series of PCR reactions to examine intron insertion,
orientation, and presence or absence of cryptic and pDFTT3 plasmids. Maps of the wild
type incA locus (a), incA::GII(bla) locus (c), C. trachomatis cryptic plasmid (b), and
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pDFTT3 (d) show the location and expected product size of all PCR reactions
performed. Figure taken from Johnson and Fisher (Johnson and Fisher, 2013).

Southern blots were performed using three different restriction enzymes and
probed for incA and the bla resistance cassette. The size shift of incA between parental
strain ACE051 and mutant strains DFCT3 and DFCT4 was apparent after probing with
an incA-specific DNA probe. The probe-bound fragment of both mutant strains ran at a
higher molecular weight than did that of the parental strain, indicating the presence of
the group II intron (Figure 3.2C-E). A probe specific for the ampicillin resistance
cassette (bla) within the intron bound to DNA fragments only present in the mutant
strains. In addition, the observation of a single bla fragment for each mutant indicates
that only a single insertion event occurred (Figure 3.2C-E).
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Figure 3.2: Southern blot verification of incA size and bla presence. (a) A map of the
wild type incA locus with the location of probe binding, as well as bla probe binding
upon intron insertion. (b) Expected product sizes after digestion. Genomic DNA from
mutant and parental strains was digested with either SacI, PstI, or SphI and run on
agarose gels, stained with ethidium bromide, and viewed with UV transillumination.
DNA was then transferred to a nylon membrane, probed with DIG-labeled probes
against incA or bla, and detected using anti-DIG antibodies conjugated to alkaline
phosphatase. Probe association was visualized with chromogenic substrate. (c-e) DNA
gels are shown alongside their respective Southern blots for all enzymes. Figure taken
from Johnson and Fisher (Johnson and Fisher, 2013).

Sanger sequencing was performed on pUC18 vectors carrying incA regions
amplified from the parental and mutant strains. The inserts in mutant strains DFCT3 and
DFCT4 had identical sequences and were also found to have inserted at the predicted
location within the chromosome (position 108 within the incA open reading frame).
Sequences were published by Johnson and Fisher (Johnson and Fisher, 2013).

Phenotypical analysis
Western blots confirmed the loss of IncA production. Protein samples from
infected cells or mock-infected cells were run on three 12% SDS-PAGE gels. One was
stained with Coomassie Brilliant Blue and imaged to confirm equal loading of samples
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(Figure 3.3A). The other two gels were processed for Western blotting: one for antiMOMP and the other for anti-IncA antibody treatment. Treatment with anti-MOMP
assured the presence of Chlamydia in all loaded samples (Figure 3.3B). Finally, antiIncA antibody failed to detect any IncA protein in the samples obtained from cells
infected with the incA::GII(bla) mutants, but did react with the ACE051 parental strain
sample (Figure 3.3C). These results indicate that the GII intron insertion into incA on the
chromosome resulted in disrupted production of IncA. Consistent with the absence of
detectable IncA by Western blot, the non-fusogenic phenotype also was observed via
light microscopy as well as immunofluorescence (Figure 3.4 and 3.5).

Figure 3.3: Western blot analysis of IncA function. Fibroblast L2 cells were infected with
mutant strains, parental strain, or mock infected at an MOI of ~10. At 24 hours post
infection, cells were lysed with Laemmli buffer and run on three 12% SDS-PAGE gels.
One gel was stained with Coomassie Brilliant Blue (a). The other two gels were
transferred to nitrocellulose membranes for anti-MOMP (b) or anti-IncA blotting (c). The
predicted masses of MOMP and IncA are 42.5 kDa and 30.3 kDa, respectively. Figure
taken from Johnson and Fisher (Johnson and Fisher, 2013).
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Figure 3.4: IncA-null phenotype observed via phase contrast light microscopy. L2 cells
were infected with parental strain ACE051 or mutant strains DFCT3 and DFCT4 at
MOIs of ~10 (a-c), ~5 (j), or ~0.1 (d-i). Images were taken under 400× magnification
with phase contrast microscopy at 24 (a-f) or 48 hours (g-j) post infection. Arrows
indicate inclusions. Figure taken from Johnson and Fisher (Johnson and Fisher, 2013).
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Figure 3.5: Immunofluorescence analysis of the incA::GII(bla) mutant phenotype.
ACE051, DFCT3, and DFCT4 were used to infect cells at an MOI of ~10. Cells were
fixed at 24 hours post infection for treatment with mouse anti-MOMP (visualized with
Texas Red-conjugated goat anti-mouse secondary antibody) for Chlamydia detection
(b, e, h), followed by DAPI staining (a, d, g). For image overlays in panels c, f, and i,
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DAPI was false colored blue and anti-MOMP was false colored red. Blue arrows
indicate cell nuclei while red arrows indicate chlamydial inclusions. Images were taken
at 630× magnification under oil immersion using a fluorescent microscope. Infection and
immunofluorescence was carried out three times. Figure taken from Johnson and Fisher
(Johnson and Fisher, 2013).

In vitro and in vivo growth properties
Plaque size
After examining the genotype and phenotype of the incA::GII(bla) mutant, the
question arose of whether this strain would be attenuated due to lack of IncA
expression. The ability to plaque was tested by measuring the size of individual plaques
of the mutant strain grown under the same conditions, and measured alongside the
parental strain. Plaques were measured at the longest point, from end to end. The data
are representative of three separate trials in which dishes were infected in duplicate.
Data were analyzed with a Student’s t-test for significance (p-value of 0.05). The
mutant strain produced plaques that were not significantly different in size than plaques
produced by the parental strain (Figure 3.6A). The incA:GII(bla) non-fusogenic
phenotype was apparent when plaque dishes were viewed at 400× magnification
(Figure 3.6B).
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Figure 3.6: Comparison of mutant and wild type strain plaque sizes. DFCT3 and
ACE051 were used to infect cells in 60 mm plaque dishes. Dishes were incubated for
two weeks and fed on days five and ten post infection. On day 14, dishes were
processed and allowed to dry after overlay removal. Processed, dry plaque dishes were
overturned and viewed on a light source and 10 random plaques were measured per
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dish. Infections were performed in duplicate and the experiment was repeated three
times. (a) Average plaque size. (b) Phase contrast micrograph of mutant plaque
phenotype at 400× magnification. White arrows indicate cells containing multiple nonfusogenic inclusions. Error bars represent standard error, n=3.

Progeny production
In addition to plaquing ability, the incA::GII(bla) mutant was assessed for its
ability to produce infectious progeny at numbers similar to that of the wild type strain.
Progeny production was assessed in vitro by infecting confluent fibroblast L2
monolayers with either wild type or mutant strain at MOIs of ~0.1 and ~3-5. Infections
were harvested at 40 hours post infection and titered. The harvested EBs were titered
alongside a portion of the dilution used to infect that well to allow for direct comparison.
The production was expressed in terms of infectious progeny harvested per EB used for
infection.
When data were analyzed using a Student’s t-test (p-value of 0.05), the ratio of
infectious progeny produced by the incA::GII(bla) mutant was not found to be
significantly different than the parental strain (Figure 3.7). Both plaque size and progeny
production results suggest that the mutant strain was not attenuated in an in vitro
infection model compared to the wild type strain.
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Figure 3.7: Wild type and mutant in vitro progeny production. Cells were infected in a
24-well plate with wild type and mutant strains at MOIs of ~0.1 and three to five. Wells
were harvested at 40 hours post infection via Triton X-100 and scraping. Harvests and
input samples were both titered via the IFU assay. Infections were performed in
duplicate and the experiment repeated three times. Error bars represent standard error,
n=3.

Animal infection model
To determine whether the incA::GII(bla) strain behaved similarly in an animal
infection model as it did in vitro, BALB/c mice were infected with either the wild type
strain or mutant strain. Vaginal swabs were taken every three days from day three post
infection through day 33. The number of infectious progeny obtained with the swabs
was determined via IFU assay.
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The yield in terms of IFU/mL differs from trial one to trial two, but the general
trend is very similar (Figure 3.8). In both cases, the swabs taken from mice infected with
the wild type strain of C. trachomatis contained a higher number of infectious progeny
throughout the first half of the infection than did those taken from mice infected with the
incA::GII(bla) strain. These data suggest that the mutant strain is attenuated for growth
in the mouse infection model, but not in a mouse fibroblast L2 cell culture infection
model.
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Figure 3.8: Animal model infection. BALB/c mice were infected vaginally with wild type
and mutant strains. Swabs were taken every three days from day three to day 33 post
infection and titered via the IFU assay. Results from experiment one (a) and experiment
two (b) with wild type in red and incA::GII(bla) mutant in blue. Five to six mice were
infected per experimental group. Error bars indicate standard deviation.
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Intron stability
The in vivo infection data suggest that the wild type C. trachomatis produces
more infectious progeny through day 15. After day 15, the number of progeny produced
by the incA::GII(bla) mutant appears much more similar to the wild type strain.
To test for the presence of the intron and maintenance of an IncA-null phenotype
throughout in vivo infection, swabs taken from the mice were used to infect confluent
monolayers of fibroblast L2 cells and expanded until several inclusions were visible per
field under 400× phase contrast microscopy. At that point, the wells were harvested and
DNA isolated. The isolated chlamydial DNA was used in PCR reactions using primers
flanking the GII(bla) insertion site within incA. Figure 3.9 shows the results from swabs
taken from both wild type and mutant C. trachomatis infections. The wild type swabs
from days nine and twelve produced a fragment size consistent with wild type incA. The
PCR product from the mutant swabs from days six and nine ran at a size indicating the
presence of the GII(bla) insert (Figure 3.9A). Swabs taken from incA::GII(bla)-infected
mice on days 24 and 27 were tested as those were time points in which the progeny
production of the mutant approached that of the wild type strain. Again, the PCR
fragments generated in this reaction ran higher than the wild type incA, indicating that
the GII(bla) insert had not been lost (Figure 3.9B).
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Figure 3.9: Genotype analysis to confirm the incA::GII(bla) mutation in mouse swab
expansions. Swabs taken from infected mice were expanded in fibroblast L2 cells and
harvested. Once detectable levels of inclusions were present, the harvests were
processed for use in PCR reactions to test for GII insert presence at time points early in
infection (a) and late in infection (b). Experimental sample labels indicate the day (D) on
which the swab was taken, whether the mouse was from the group inoculated with the
wild type (WT) or mutant (M) strain, and the mouse number.

Complementation
It was important to demonstrate that all of the observed incA:GII(bla)
characteristics were due solely to the absence of IncA. Manipulation of any gene has
the potential for unseen effects outside of the target gene. As a result, expression of the
wild type incA gene from a plasmid resulting in restoration of the wild type phenotype
can ensure that the GII(bla) insertion had no unexpected results, such as polar effects,
on the expression of other genes.
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Upon the fourth passage of the incA::GII(aadA) mutant strain carrying either
p2TK2-SW2 or p2TK2-SW2::incA in tissue culture, the phenotype difference became
apparent as every cell was infected with an MOI ~3. The strain carrying empty p2TK2SW2 vector retained the non-fusogenic inclusion phenotype characteristic of the IncAnull mutant C. trachomatis (Figure 3.10A). The strain carrying the complementation
vector p2TK2-SW2::incA, however, appeared to display a phenotype consistent with
that of wild type C. trachomatis (Figure 3.10B). In this complemented strain, every cell
appeared to contain only a single inclusion despite having an MOI >1.
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Figure 3.10: Complementation of the incA::GII(aadA) mutant. Chemical transformation
was used to move p2TK2-SW2 or p2TK2-SW2::incA into DFCT9. Transformants
carrying p2TK2-SW2 (a) or p2TK2-SW2::incA (b) were selected with ampicillin and
passaged in fibroblast L2 cells until the phenotype could be visualized. Images were
taken under phase contrast microscopy at 400× magnification.
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CHAPTER 4
DISCUSSION
Despite being treatable with antibiotics such as azithromycin and doxycycline,
Chlamydia trachomatis infections continue to pose a threat to public health. Infections
left untreated due to asymptomatic presentation or lack of access to antibiotics may
cause a wealth of complications including blinding trachoma for ocular infections, and
ectopic pregnancy, pelvic inflammatory disease, and infertility for sexually transmitted
infections (Burton and Mabey, 2009; Chow et al., 1990; Healy et al., 1994; Paavonen
and Lehtinen, 1996). Additionally, Chlamydia may enter into a persistent state in which
the bacteria do not replicate, but may begin growing again when the inhibitor is
removed, such as when antibiotics are no longer present (Hogan et al., 2004). While
antibiotic resistance has not yet been seen in C. trachomatis, some strains of
Chlamydia suis carry a gene that confers resistance to tetracycline (Suchland et al.,
2009). Further, it has been shown that the tet(C) gene from C. suis is capable of being
horizontally transferred to other species of Chlamydia (C. trachomatis and C.
muridarum) in co-infection experiments, indicating that acquisition of antibiotic
resistance genes is feasible (Suchland et al., 2009).
Recently, research has been done suggesting that the gastrointestinal tract may
in fact be a reservoir for Chlamydia, resulting in long-term colonization (Yeruva et al.,
2013b). Animals are known to become infected in the GI tract with Chlamydia via the
fecal-oral route. Interestingly, azithromycin treatment at levels sufficient for clearing
genital tract infections was found to be ineffective for clearing GI tract infections in mice
(Yeruva et al., 2013a). Presence of Chlamydia in the GI tract has also been confirmed
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in humans (Rank and Yeruva, 2014). Since azithromycin has been shown to be
ineffective at clearing GI tract infections, individuals may still be at risk for reinfection, as
well as infection of sexual partners, even after successful antibiotic treatment for genital
infections.
Due to the problems associated with detection and antibiotic treatment of
infections, prevention of infection would be desirable. While vaccines currently exist for
C. abortus and C. felis for use in animals, vaccine development and basic research in
general has been hindered due to a lack of tools for genetic manipulation and lack of
axenic growth conditions, until more recently (Longbottom and Livingstone, 2006;
Omsland et al., 2012). Chemical mutagenesis has been employed to introduce random
chromosomal mutations, antisense RNA has been used for gene silencing, and cryptic
plasmid-based expression platforms have been developed for gene expression
(Agaisse and Derré, 2013; Kari et al., 2011; Mishra et al., 2012). Still, the field lacked a
method of creating targeted chromosomal mutations. To address this deficiency, we
modified the TargeTron™ system for use in Chlamydia to allow for targeted gene
inactivation.
Use of the TargeTron™ system in Chlamydia enables researchers to target and
inactivate genes without the cost and time associated with TILLING-based mutagenesis
approaches. In addition, the use of multiple selection markers would enable the targeted
inactivation of multiple genes. There is also potential for the study of expression when
combined with the recent development of a tetracycline-inducible on/off system
(Wickstrum et al., 2013). The stability of the intron makes it ideal for use in animal
model infections. However, it would still be less than ideal for use in developing a live-
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attenuated vaccine. In such cases, a complete deletion achieved by a method such as
allelic exchange would be desirable. Despite the stability of the intron observed in our
study, a true deletion eliminates any possibility of restoration of the complete wild type
gene transcript.
As proof of principle, incA was targeted for inactivation because naturallyoccurring IncA mutant clinical isolates have been found (Suchland et al., 2000). This
indicated that insertionally inactivating the incA gene would not be lethal for the
bacterium. Furthermore, C. trachomatis isolates that lack functional IncA possess a
readily observable non-fusogenic inclusion phenotype. Microinjection experiments with
anti-IncA supported IncA’s role in fusion of multiple inclusions in a host cell upon
infection with multiple EBs (Hackstadt et al., 1999). Our creation and examination of an
isogenic incA::GII(bla) mutant further supports the role of IncA in chlamydial inclusion
fusion (Johnson and Fisher, 2013).
The creation of incA::GII(bla) mutants was performed in several independent
trials by different members of the lab using independently-prepared EB stocks, buffers,
as well as pDFTT3 plasmid DNA preparations. The mutants were first examined visually
after several passages under ampicillin selection for the presence of the IncA-null
phenotype. The characteristic non-fusing inclusions were apparent under light
microscopy as well as immunofluorescence microscopy (Figure 3.4 and 3.5). Genotypic
analysis of genomic DNA isolated from mutants DFCT3 and DFCT4 confirmed the
single insertion of the GII(bla) within incA via Southern blot (Figure 3.2). PCR and
sequencing determined that the insertion event occurred at the predicted location and in
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the correct orientation and that pDFTT3 was lost (Figure 3.1). Finally, Western blot
analysis confirmed the loss of IncA production (Figure 3.3).
Reintroduction of the incA gene via transformation of p2TK2-SW2::incA into the
mutant strain resulted in the production of functional IncA (detected via Western blot,
data not shown, D. Fisher) as well as restoration of the wild type fusogenic inclusion
phenotype (Figure 3.10). Complementation was essential in ensuring that the mutation
within incA did not result in any secondary mutations or polar effects in other genes.
The latter point is of greater concern for genes that lie within an operon, which incA
does not. Complementation studies have been extremely limited in C. trachomatis and
this is only the third instance of complementation (Chen et al., 2014; Snavely et al.,
2014).
After genotypic and phenotypic analysis of the incA::GII(bla) mutant, further
characterization of the mutant was performed to examine its pathogenicity in vivo and in
vitro compared to the wild type strain. Plaque dish infection assays indicated that the
mutant strain produced plaques that were not significantly different in size than those of
the wild type strain (Figure 3.6). However, the plaques were only measured in one
dimension. Future studies should measure plaque area as the mutant plaques did show
a larger-size trend and area might be a more accurate way to compare plaque size. At
the very least, growth was not attenuated in the mutant strain in the plaque assays.
Production of infectious progeny was examined in vivo and in vitro. Infections of
mouse fibroblast L2 cells demonstrated that the incA::GII(bla) mutant progeny
production trend was greater than that of the wild type strain, but like the plaque results,
not different in a statistically significant manner (Figure 3.7). Intriguingly, swab titers
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from mouse infection experiments were higher for the wild type strain than for the
mutant during the first few weeks of infection (Figure 3.8). Unlike the cell culture trends,
the differences between the wild type strain and mutant strain titers in the animal model
were statistically significant using repeated measures two-way ANOVA with Bonferroni
correction (p-value of 0.05) (L. Yeruva, unpublished). Thus, the incA::GII(bla) mutant
appeared to be attenuated for growth in vivo, but not in vitro.
C. trachomatis clinical isolates that possess a non-fusogenic phenotype occur at
a frequency of approximately 1.5%, higher than frequencies indicative of random
mutations (Suchland et al., 2000). These isolates persist in clinical infection, but always
at a similar frequency while the wild type continues to predominate. This implies that the
wild type strain has the advantage under most conditions, but not all, or the mutant
phenotype would be absent or present at considerably lower frequency. The cell culture
data from our study would support an advantage for the IncA-null mutant over the wild
type strain, but fails to take the innate and adaptive immune responses into account.
The animal model may more accurately reflect what occurs in human infections in terms
of the immune response as it appears to significantly affect the success of the mutant
strain. It is possible that early response by members of the innate immune system, such
as polymorphonuclear leukocytes (PMNs), to greater production of infection progeny by
the mutant strain results in decreased titers compared to the wild type strain (Rank et
al., 2011). Then, at later time points in which the adaptive immune response, including
CD8+ T-cells, respond to IncA, the wild type strain titers decrease more dramatically
relative to the IncA-null strain (Wizel et al., 2002).
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Initially, we hypothesized that the IncA-null strain would demonstrate attenuated
growth in a cell culture infection model. We hypothesized that the presence of multiple
inclusions within a single host cell would result in more competition for the scavenging
of host nutrients when compared to a single, larger inclusion within a host cell.
However, our data did not support this hypothesis and indicated that the exact opposite
may be true. Instead of increased competition, the presence of multiple inclusions may
provide a greater total surface area per bacterium across which to move nutrients from
the host. This greater surface area to volume ratio would theoretically allow for more
efficient nutrient uptake and could explain the increased progeny production by the
mutant. This could be tested by calculating the actual surface area of the non-fusogenic
inclusions within a single host cell compared to that of a single wild type inclusion.
Additionally, the increased progeny numbers could be due to greater RB
production per inclusion prior to conversion to EBs. Hoare et al. have hypothesized that
the triggering factor for RB to EB differentiation is decreased contact between the RB
and the inclusion membrane as inclusion size increases (Hoare et al., 2008). Thus, after
an EB has differentiated into an RB, it may undergo replication only as long as a certain
amount of contact is maintained with the inclusion membrane. As bacterial load
increases within the inclusion, it grows to accommodate them and decreases physical
contact with each RB. At a certain threshold of contact, the RBs then begin
differentiating back into EBs. In the context of our findings where the non-fusogenic
incA::GII(bla) strain may produce more progeny than its fusogenic parental strain, this
hypothesis may provide a possible explanation. The presence of multiple, smaller
inclusions within the same host cell would allow more contact per RB with the inclusion
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membrane. This would enable a greater number of replication events to occur before
the threshold is met to signal RB to EB differentiation. This hypothesis could be tested
by using the original model to determine how many RBs could be supported within the
multiple non-fusogenic inclusions verses the single inclusion before they being to
differentiate into EBs. This could then be tested experimentally by infecting cells with
mutant and wild type strains at different MOIs to compare actual progeny production
versus the calculated output based on number of inclusions.
In contrast to the cell culture infection model, the animal model infections showed
that the mutant strain was attenuated for growth compared to the wild type strain during
the first two weeks of infection. However, the titers of wild type and mutant strains
leveled off and appeared similar during the second half of the infection, raising concerns
about the stability of the intron in vivo. It was possible that the incA::GII(bla) mutant
strain lost the GII(bla) insert at some point during the infection, allowing restoration of
the incA gene and production of functional IncA. This would explain why the titers
appeared similar for only the last half of infection. We were able to disprove this by
genotypic and phenotypic analysis of the vaginal swabs taken from the infected mice.
Swabs taken from the incA::GII(bla) strain-infected mice at time points late in the
infection, points at which mutant and wild type strain titers became similar, still
displayed the non-fusogenic mutant phenotype upon expansion in cell culture. Further,
the genomic DNA isolated from those same swabs was found to have retained the
intron. Thus, we concluded that similar titers of mutant and wild type strains seen late in
infection were not a result of mutant strain reversion to wild type as a result of intron
loss.
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Another possibility is that growth of the wild type strain decreased during the
second half of infection, resulting in a clearance rate equal to the mutant strain. Sera
from C. trachomatis-infected patients have been found to contain antibodies against
IncA (Bannantine et al., 1998). Also, the IncA homolog found in C. pneumoniae is a
known CD8+ T-cell antigen (Wizel et al., 2002). If the adaptive immune system (which
typically takes approximately ten days to develop) does in fact respond to IncA during
infection, this could explain why the wild type titers from the animal infection model were
reduced to levels matching those of the mutant IncA-null strain. To test this hypothesis,
sera from mice infected with the wild type and mutant strains could be assessed for
anti-IncA reactivity.
The in vitro data indicating that the mutant grows as well or better than the wild
type strain were not mirrored in the results observed during the first half of the animal
model. One possible explanation for the disadvantage of the incA::GII(bla) mutant strain
during the first two weeks of infection in vivo could be an increased rate of progeny
production during early infection. In a cell culture infection model, responses by the
innate and adaptive immune system are absent. Thus, increased numbers may fail to
elicit a response similar to what would occur in vivo. For early infection time points, the
innate immune system would be responsible for bacterial clearance. For chlamydial
infections in particular, PMNs have been found to be important for early clearance
(Rank et al., 2011). If this innate immune system was triggered more strongly by the
presence of increased progeny numbers by the mutant during the first 48 hours of
infection, the production of fewer progeny by the wild type strain might allow that strain
to persist more efficiently than the mutant strain. Examination of tissue sections during
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the first 24-72 hours of infection to measure PMN influx should be performed in future
studies.
Collectively, this research project has resulted in the development of a tool for
creating targeted chromosomal mutations in Chlamydia and has demonstrated the
applicability of this method for delineating aspects of chlamydial pathogenesis through
study of the incA::GII null mutant.
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